Alpha-1-antitrypsin deficiency in aneurysmal disease

Area of Science:

• Genetics
• Vascular Biology
• Protease Inhibitor Research

Background:

• Alpha 1-Antitrypsin (alpha 1-AT) deficiency is implicated in arterial aneurysmal disease due to increased proteolysis of arterial proteins.
• Alpha 1-AT levels are genetically determined by variations at the Protease Inhibitor (PI) locus.

Purpose of the Study:

• To investigate the association between PI phenotypes and the risk of abdominal aortic aneurysms (AAAs) and intracranial aneurysms (IAs).
• To determine if PI phenotype influences the age of diagnosis for arterial aneurysms.

Main Methods:

• PI phenotypes were analyzed in 173 patients with AAAs and 72 patients with IAs from Pittsburgh and London.
• Allele frequencies of PI deficiency variants were compared between patient cohorts and controls.
• Statistical analysis was performed to assess the impact of PI phenotype and smoking history on aneurysm age-at-diagnosis.

Main Results:

• No increased frequency of PI deficiency alleles was found in patients with AAAs or in the Pittsburgh IA cohort.
• A trend for higher PI*Z deficiency allele frequency was observed in the London IA cohort compared to controls, but this was not statistically significant after multiple comparisons correction.
• PI phenotype did not affect the age of aneurysm diagnosis in any of the studied groups.
• Smoking history significantly impacted the age of diagnosis only in the Pittsburgh IA group.

Conclusions:

• The study did not find a significant link between alpha 1-Antitrypsin deficiency and the risk of abdominal aortic or intracranial aneurysms.
• While a trend was noted in one subgroup, PI phenotype does not appear to be a major determinant for aneurysm development or age of diagnosis.
• Smoking remains a significant factor influencing aneurysm diagnosis age in specific patient populations.